Martin Schuler

LIONS PREY: A New Logistic Scoring System for the Prediction of Malignant Pulmonary Nodules

G. Schlachtenberger, Khosro Hekmat, Hruy Menghesha, 2024, Cancers.

Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma.

C. Pirker, B. Hegedüs, C. Blanquart, 2023, Lung cancer.

C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy

M. Wiesweg, N. Guberina, M. Guberina, 2024, Scientific reports.

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

K. Darwiche, T. Gauler, M. Schuler, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease

T. Gauler, M. Wiesweg, N. Guberina, 2024, Cancers.

Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis

C. von Kalle, D. Rieke, W. Hoffmann, 2023, The Lancet regional health. Europe.

Closing the RCT Gap—A Large Meta-Analysis on the Role of Surgery in Stage I–III Small Cell Lung Cancer Patients

G. Schlachtenberger, M. Michel, Khosro Hekmat, 2024, Cancers.